Immunomodulation and therapeutic characterization of thymosin fraction five.

In this report we describe the characterization of the immunomodulatory efficiency and therapeutic properties of thymosin fraction five (F5). We consistently observed the immunostimulation of T-cell activity in assays of allogeneic mixed lymphocyte response (MLR) and the development of cytotoxic effector cells in an allogeneic mixed lymphocyte tumor response-cell-mediated cytotoxicity assay (MLTR-CMC). No induction of suppressor cell activity was observed. Thymosin F5 also acted successfully as an adjuvant when admixed with irradiated tumor cells. We were unable to demonstrate either NK cell or macrophage activation by thymosin F5. Therapeutic protocols using thymosin F5 and directed against pre-existing experimental and spontaneous metastases, had a significant immunotherapeutic potential.
AuthorsJ E Talmadge, K A Uithoven, B F Lenz, M Chirigos
JournalCancer immunology, immunotherapy : CII (Cancer Immunol Immunother) Vol. 18 Issue 3 Pg. 185-94 ( 1984) ISSN: 0340-7004 [Print] GERMANY, WEST
PMID6239686 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • thymosin fraction 5
  • Thymosin
  • Animals
  • Cell Line
  • Fibrosarcoma (therapy)
  • Immunotherapy
  • Leukemia, Experimental (therapy)
  • Lymphocyte Culture Test, Mixed
  • Male
  • Melanoma (therapy)
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred C57BL
  • Neoplasm Metastasis
  • Neoplasms, Radiation-Induced (therapy)
  • T-Lymphocytes (immunology)
  • Thymosin (analogs & derivatives, therapeutic use)
  • Ultraviolet Rays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: